Journal: bioRxiv

Article Title: The binding mechanism of Streptococcus suis accessory virulence factor and adhesin SadP to globotetraosylceramide

doi: 10.1101/2020.05.29.122762

Figure Lengend Snippet: POPC/glycolipid liposomes (4, 0.4 and 0.04 nmol/dot) and POPC/cholesterol/globosylceramide liposomes (4, 0.4 and 0.04 nmol/dot) were applied onto PVDF membrane. WT, His-tagged SadP(125-329) type P N ; N285D, site-specific mutant of SadP(125-329); Replicate membranes containing dotted liposomes with or without cholesterol (see Methods) were probed with SadP and SadP N285D . The bound proteins were detected with anti-His and HRP-labelled antibodies as described in the methods and membrane was imaged with FujiLAS-4000. The globo series glycolipids used were: Gb4, d18:1-24:0 + d18:1 – 16:0; Gb3/1, Gb3 d18:1-24:0; Gb3/2, Gb3 d18:1-16:0; Gb3/3, Gb3 d18:1-h16:0.

Article Snippet: Finally, streptavidin donor beads were added (20 μg/ml) and the mixtures were incubated for 30 mins and were then measured with the Ensight multimode reader (Perkin Elmer) using excitation wavelength of 680 nm with donor beads and measurement of emission wavelength of 615 nm from AlphaLISA anti-HIS acceptor beads.

Techniques: Mutagenesis

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Expression levels of SPDL1 mRNA in PAAD tumors and normal tissues. A SPDL1 mRNA expression in TCGA cohort. B SPDL1 mRNA expression in GSE15471 cohort. C SPDL1 mRNA expression in GSE62165 cohort. D The graph presents a bar chart of SPDL1 expression distribution across PAAD cell lines, Both the height and color of the bars indicate the magnitude of SPDL1 expression, with the median serving as the cutoff point. P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Representative immunohistochemical images showing SPDL1 expression in tumor-adjacent tissues and pancreatic adenocarcinoma (PAAD) tissues. A SPDL1 staining in adjacent tissues. B SPDL1 weak staining in PAAD tissues. C SPDL1 strong staining in PAAD tissues. The expression of SPDL1 in PAAD tissues with different Ki-67 expression. *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Immunohistochemical staining, Expressing, Staining

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Single-cell expression analysis of SPDL1 in PAAD. A The UMAP plot of single-cell clustering in GSE148673 . B UMAP plot showing SPDL1 expression distribution across distinct cell types in GSE148673 . C AUCell score for tumor proliferation signature in different cells in GSE148673 . D The UMAP plot of single-cell clustering in GSE154778 . E UMAP plot showing SPDL1 expression distribution across distinct cell types in GSE154778 . F AUCell score for tumor proliferation signature in different cells in GSE154778 . G SPDL1 expression across distinct cell types in GSE148673 . H Differential analysis of tumor proliferation-related signaling pathways between SPDL1-positive and SPDL1-negative cell groups in the GSE148673 . I SPDL1 expression across distinct cell types in GSE148673 . J Differential analysis of tumor proliferation-related signaling pathways between SPDL1-positive and SPDL1-negative cell groups in the GSE148673

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Single Cell, Expressing, Protein-Protein interactions

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: The correlation of SPDL1 mRNA expression with clinical parameters from the TCGA cohort, including ( A ) Age, ( B ) Sex, ( C ) T stage, ( D ) N stage, ( E ) M stage, ( F ) TNM stage. *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Expression is associated with the prognosis of PAAD patients. A Kaplan-Meier survival curves of OS between high and low SPDL1 expression groups. B Kaplan-Meier survival curves of DSS between high and low SPDL1 expression groups. C Kaplan-Meier survival curves comparing PFI between high and low SPDL1 expression groups. D Univariate and Multivariate Cox regression analysis (overall survival) for prognostic factors in PAAD. E Independent risk factors were evaluated for OS using multivariate Cox regression and were combined into the nomogram model. F ROC curves and nomogram AUC values for predicting 1-, 2-, and 3-year OS. G Calibration charts for the nomogram depicting 1-year, 2-year and 3-year OS. H DCA for the nomogram depicting 1-year OS. I DCA for the nomogram depicting 2-year OS. J DCA for the nomogram depicting 3-year OS

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: GSEA and GSVA analysis. A GSEA analysis revealed that the tumor proliferation pathway is enriched in the SPDL1-high expression group. B Relationship between SPDL1 expression and tumor proliferation score

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Effect of SPDL1 Silencing on PAAD Cell Proliferation in PAAD. A Western blot analysis showing that SPDL1 protein expression was significantly reduced in PANC-1 cells following transfection with si-SPDL1 compared with control group. B CCK-8 assays demonstrated that SPDL1 silencing markedly inhibited cell viability in PANC-1 cells over time (24, 48, and 72 h), with significant reduction at 24 h compared with control group. C , D Colony formation assays indicated that SPDL1 knockdown significantly reduced the number of colonies formed. E , F EdU incorporation assay reveals SPDL1 knockdown significantly reduced the ratio of cell proliferation. For ( A ), ( B ), ( D ), and ( E ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Western Blot, Expressing, Transfection, Control, CCK-8 Assay, Knockdown

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Knockdown expression of SPDL1 inhabited the migration and invasion of PANC-1 cells. A Wound healing assays showed that SPDL1 knockdown significantly delayed wound closure at 24 h, indicating impaired migration. B Transwell invasion assays showed that SPDL1 silencing significantly decreased the number of invading PANC-1 cells. For ( A ) and ( B ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Knockdown, Expressing, Migration

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: SPDL1 activates the AKT/mTOR signaling pathway. A Gene Set Enrichment Analysis (GSEA) based on TCGA dataset revealed that the PI3K/AKT/mTOR signaling pathway was significantly enriched in the SPDL1 high-expression group relative to the SPDL1 low-expression group. B Western blot assay was performed to detect the protein expression levels of AKT, phosphorylated AKT (p-AKT), mTOR, and phosphorylated mTOR (p-mTOR) in PANC-1 cells following different transfection treatments. For ( B ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing, Western Blot, Transfection

Journal: Cell

Article Title: Microtubule-induced Pins/Galphai cortical polarity in Drosophila neuroblasts.

doi: 10.1016/j.cell.2005.09.043

Figure Lengend Snippet: Figure 1. Astral Microtubules Induce Pins/Gai/Dlg Cortical Polarity in Neuroblasts (A–N) Lateral view of stage 10 metaphase neuroblasts. Genotypes and/or drug treatments are listed above panels. (F and G) Colcemid (COL) and (K and L) 20 mM nocodazole (NOC). Markers are listed within each panel, and double-labeled neuroblasts are shown in the bottom row of (A)–(G) and (K)–(N); the mitotic marker phospho-histone H3, PH3. Crescents are indicated by arrowheads, and neuroblasts without crescents are in brackets in this and all subsequent figures. (O) Quantitation of the Pins crescents formed in each genotype with or without drug; number of neuroblasts scored indicated within each bar. Apical is up and scale bar is 10 mm in this and subsequent figures unless noted.

Article Snippet: Primary antibodies used for these studies include rabbit phospho-Histone H3 (1:1,000; Upstate), mouse a-tubulin (1:2,000; Sigma-Aldrich), rat a-tubulin (1:100; Serotec), mouse g-tubulin (1:2,000; Sigma-Aldrich), rabbit Pins (Yu et al., 2000), rat Pins (1:500; F. Yu), rabbit Gai (Schaefer et al., 2001), mouse Dlg 4F3E2 (Parnas et al., 2001), rabbit Insc (1:500; W. Chia), rabbit anti-Baz (1:500; A. Wodarz), rabbit aPKC (1:500; Santa Cruz), rat Par-6 (Rolls et al., 2003), and guinea pig Senseless (Nolo et al., 2000).

Techniques: Labeling, Marker, Quantitation Assay

Journal: NPJ Parkinson's Disease

Article Title: Imaging mass cytometry reveals generalised deficiency in OXPHOS complexes in Parkinson’s disease

doi: 10.1038/s41531-021-00182-x

Figure Lengend Snippet: IMC antibody panel for this study.

Article Snippet: Anti-Histone H3- 171 Yb (D1H2; AB_2811058) , Nuclear marker , 3176023D, Fluidigm , 0.5 mg/ml , / , 4 µg/ml.

Techniques: Concentration Assay, Marker